Dr Fabian Kausche joined GALVmed’s Board in September 2020 and has been a member of the Technical Scientific Advisory Committee since March 2020.
He is Chairman of the Board of PetMedix, a start-up company in Cambridge, UK developing monoclonal antibodies for animals; and Stonehaven Incubate, AG, an incubator bringing breakthrough human health technologies to animal health. He owns and runs FK Consulting, LLC a company located in Atlanta specializing in supporting animal health companies in product innovation and organizational efficiency strategies. He also works as scientific advisor for Rejuvenate Bio, a California-based startup that develops modern gene therapies for companion animals.
Dr Kausche has several decades of senior executive experience in the animal and human health industries in both biological and pharmaceutical research and development. He has held positions as Global Head of Research & Development for three of the top eight global Animal Health companies: Novartis Animal Health, Merial, and Boehringer Ingelheim Animal Health. Before leaving Boehringer Ingelheim Animal Health, he led the post-merger integration of the largest R&D organization in the Animal Health industry with more than 1,200 scientists and support staff. He gained additional expertise in the human health space as head of R&D for Novartis Consumer Health. Prior to that, he also successfully led a companion animal sales force for Novartis Animal Health.
A native of Germany, Dr Kausche received a veterinary degree from the Hannover Veterinary School. He subsequently completed a Master of Science degree at Iowa State University. Following the completion of the M.S. degree, Dr Kausche returned to Europe and took part in a research program that led him to receiving the German PhD (Dr.med.vet.) in a combination program between the Hannover Medical and Veterinary Schools. Having completed the Advanced Management Program in 2005, he is also an alumnus of Harvard Business School.
Dr Kausche currently resides in Atlanta, USA.